Akums Drugs and Pharmaceuticals, which describes itself as India’s largest contract development and manufacturing organisation (CDMO), reported a 168% year-on-year jump in second-quarter FY27 profit after tax to ₹115 crore, as its CDMO business grew 38.6% and operating margins widened sharply. The results cover the quarter ended 30 September 2026.

Akums Q2 FY27 results at a glance

• Consolidated revenue rose 31.9% to ₹1,342 crore, from ₹1,018 crore a year earlier.
• EBITDA more than doubled, up 106% to ₹195 crore from ₹94 crore.
• EBITDA margin widened to 14.5% from 9.3%, an expansion of about 520 basis points.
• Profit after tax rose to ₹115 crore from ₹43 crore, with PAT margin at 8.4% against 4.1%.

CDMO business drives the quarter

Contract manufacturing remained the main growth engine. CDMO revenue climbed 38.6% to ₹1,115 crore from ₹804 crore and now makes up about 83% of consolidated revenue, while CDMO EBITDA almost doubled to ₹168 crore from ₹84 crore. The company credited double-digit volume growth, steady customer demand and deeper penetration in the domestic market.

The performance is in line with a strong season for Indian outsourcing players. Laurus Labs reported a 75% rise in CDMO revenue for the same quarter, and Piramal Pharma returned to profit on 36% CDMO growth.

“The demand environment continues to remain robust, reflecting the growing importance of reliable manufacturing partners,” said Sanjeev Jain, Managing Director, Akums, adding that the company keeps investing in manufacturing infrastructure and capabilities for its partners.

First-half performance and global ambitions

For the first half of FY27, revenue grew 22.9% to ₹2,509 crore, EBITDA rose 65.3% to ₹369 crore and profit after tax roughly doubled to ₹216 crore from ₹107 crore.

Akums is now aiming beyond the domestic market. Managing Director Sandeep Jain said the company wants to become a globally recognised CDMO and has a pipeline of more than 30 products for European markets. The plan builds on its first overseas manufacturing facility in Zambia.

Entry into beauty and personal care manufacturing

During the quarter, Akums also moved into colour cosmetics manufacturing through its subsidiary Pure & Cure Healthcare, with the ₹56 crore acquisition of Oriflame India’s manufacturing business. The deal covers plants in Roorkee, Uttarakhand, and Noida, Uttar Pradesh, plus a leased warehouse in Noida.

Why it matters for Indian pharma manufacturing

Akums’ results show how much of India’s formulation volume now runs through contract manufacturers. With margins recovering and a European pipeline in the works, the company’s next test is whether it can win global partners and meet export-market quality standards at scale. Details of the quarter were reported by ET Pharma and Indian Pharma Post.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!